These sites and their content are provided "as is," "with all faults" and "as available." rEVO Biologics, Inc. , its licensors, and its suppliers, to the fullest extent permitted by law, disclaim all warranties, either express or implied, statutory or otherwise, including but not limited to the implied warranties of merchantability, non-infringement of third parties' rights, and fitness for particular purpose. Specifically, rEVO, its licensors, and its suppliers make no representations or warranties about the accuracy, reliability, completeness, currentness, suitability or timeliness of the content, software, text, graphics, tools, links, or communications provided on or through the use of the sites or rEVO, or on any site or sites "linked" to these sites. rEVO makes no warranty that the sites will be available, uninterrupted, non-infringing, error free, or free of viruses or other harmful components.
We do not endorse and are not responsible for the accuracy or reliability of any opinion, advice or statement on the sites. Under no circumstances will rEVO be liable for any loss or damage caused by your reliance on information obtained through either the content on the sites or use of any product described on the sites. It is your responsibility to evaluate the accuracy, completeness or usefulness of any information, opinion, advice or other content available through the sites. Please seek the advice of professionals, as appropriate, regarding the evaluation of any specific information, opinion, advice or other content on the sites.
Intellectual Property Rights & Grant
The Sites contain copyrighted material, trademarks and other proprietary information, including data, text, software, photos, video and graphics ("Content"). This Content is copyrighted, subject to registered trademarks or trade dress otherwise protected and owned by rEVO Biologics, Inc. or a third party who licensed or granted to rEVO the right to use such material.
rEVO authorizes You to copy materials published by it on the Sites for non-commercial and internal use only. This means You may not modify, publish, transmit, display, participate in the transfer or sale, create derivative works, or in any way exploit the Content of the Sites or any portion of them. You may not use any data mining, robots, or similar data gathering and extraction tools on the Content, frame any portion of the Sites or Content, or reproduce, reprint, copy, store, publicly display, broadcast, transmit, modify, translate, port, publish, sublicense, assign, transfer, sell, loan, or otherwise distribute the Content without the prior written consent of rEVO. You may not circumvent any mechanisms included in the Content for preventing the unauthorized reproduction or distribution of the Content.
In the event You make a permitted, non-commercial use of the Content, You must ensure that any such copy of the Content includes the appropriate copyright and/or other proprietary notification.
Except as expressly set forth on the Sites, if You submit any information to Us, including any comments, remarks, suggestions, ideas, notes, drawings, graphics, concepts, or other information, You are giving that information, and all Your rights in it, to rEVO free of charge and such information shall be deemed to be non-confidential and rEVO shall have no obligation of any kind with respect to such information and shall be free to reproduce, use, disclose and distribute the information to others without limitation, without Your consent or any compensation to You or anyone else. rEVO shall be free to use any know-how or techniques contained in such information for any purpose whatsoever including but not limited to developing, manufacturing and marketing products incorporating such information.
Links to Other Sites
Limitation of Liability
Choice of Law & International Visitors
The rEVO Sites are intended for use by U.S. residents only. If You are a non-U.S. resident, please be aware that although the products discussed are registered worldwide, they may not be available in particular countries, or may be approved or cleared by a government regulatory body for sale or use with different indications, dosages and restrictions. Trademarks may also vary. Therefore, the most current locally approved prescribing information should always be examined carefully. The contents contained herein, including but not limited to all product information, is for informational purposes only.
Effective Date December 2013
Indications and Usage
ATryn is a recombinant antithrombin indicated for the prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients.
It is not indicated for treatment of thromboembolic events in hereditary antithrombin deficient patients.
Important Safety Information
ATryn is contraindicated in patients with known hypersensitivity to goat and goat milk proteins. Allergic-type hypersensitivity reactions, including anaphylaxis, are possible. Patients must be closely monitored and carefully observed for any symptoms throughout the infusion period. Patients should be informed of the early signs of hypersensitivity reactions including hives, generalized urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis. If these symptoms occur during administration, treatment must be discontinued immediately and emergency treatment should be administered.
The anticoagulant effect of drugs that use antithrombin to exert their anticoagulation may be altered when ATryn is added or withdrawn. To avoid excessive or insufficient anticoagulation, coagulation tests suitable for the anticoagulant used (e.g., aPTT and anti-Factor Xa activity) are to be performed regularly, at close intervals, and in particular in the first hours following the start or withdrawal of ATryn. Additionally, patients should be monitored for the occurrence of bleeding or thrombosis in such situations.
The serious adverse reaction that has been reported in clinical studies is hemorrhage (intra-abdominal, hemarthrosis, and post procedural). The most common adverse events reported in clinical trials at a frequency of
≥ 5% are hemorrhage and infusion site reaction.
For more information, please view full Prescribing Information for ATryn.
To report suspected adverse reactions contact rEVO Biologics at 800-610-3776 or the FDA at 800-FDA-1088 or www.fda.gov/MedWatch.
For more information, please see full Prescribing Information for ATryn.
® ATryn is a registered trademark of rEVO Biologics, Inc.
rEVO Biologics is a registered trademark of LFB S.A.
For medical inquiries, please